Biotech

Startups News

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 16.08.2022.

#VicCohnPrize
#startups
#biotech
#IPO
#DrugDevelopment
#DrugDiscovery
#Funding
#CEO
#LifeSciences
#BayArea

@adamfeuerstein shared
On Aug 15, 2022
RT @ScienceWriting: And the #VicCohnPrize winners are... @PamBelluck of @nytimes and @stephaniemlee formerly with @BuzzFeedNews have been awarded the 2022 Victor Cohn Prize for Excellence in Medical Science Reporting. Congratulations to you both!! https://t.co/thmlZ1KRuK https://t.co/EUQRwCvYZ0
Open
Pam Belluck and Stephanie M. Lee share 2022 Victor Cohn Prize

Pam Belluck and Stephanie M. Lee share 2022 Victor Cohn Prize

Pam Belluck Pam Belluck began uncovering medical stories as a national bureau chief at the Times, initiating important enterprise stories on Alzheimer’s disease and mental …

@PitchBook shared
On Aug 12, 2022
📉 Our data confirms that early-stage VC valuations saw a sharp decline in the second quarter, and unicorn public exits nearly went extinct in the first half of 2022. 🦄 Yet, some counterintuitive data suggests positive economic outcomes for start-ups. https://t.co/0QeuLU9AHt
Open
Early-stage VC valuations see their first decline in 10 quarters

Early-stage VC valuations see their first decline in 10 quarters

New data shows weakness across the board, from seed stage to unicorns.

@BentheFidler shared
On Aug 10, 2022
Gemini’s fall gives Disc a way around biotech’s IPO slump https://t.co/jcBvnbTwra by @gwendolynawu $GMTX $IRON $RHHBY $ABBV
Open
Gemini’s fall gives Disc a way around biotech’s IPO slump

Gemini’s fall gives Disc a way around biotech’s IPO slump

The biotech’s failed attempt to develop an eye disease drug has ended in a reverse merger that gives startup Disc Medicine a fast path to the public markets.

@BentheFidler shared
On Aug 16, 2022
Amid market turbulence, a Flagship startup pushes off an #IPO with a new fundraise https://t.co/YOueRSeptQ by @gwendolynawu @FlagshipPioneer @sendabioscience #startups
Open
Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise

Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise

Senda Biosciences decided to raise a $123 million Series C round rather than test public markets with an initial offering, its top executive said.

@Forbes shared
On Aug 12, 2022
B2B technology company Locke Bio is building the "Shopify" for the health industry. Its technology helps organizations launch a fully integrated, branded DTC pharmacy or telehealth service. https://t.co/rZb5ev3aSS
Open
Cathy Tie Builds Locke Bio To Be ‘Shopify’ For Health industry

Cathy Tie Builds Locke Bio To Be ‘Shopify’ For Health industry

Founded in 2019 by then 23-year-old entrepreneur, Thiel Fellow and Forbes 30 under 30 member Kathy Tie, B2B technology company Locke Bio is building the "Shopify" for the health industry. ...

@BentheFidler shared
On Aug 16, 2022
This week in our emerging #biotech newsletter: a look at the (very large) group of #startups developing 'Treg' cell therapies ‘Treg’ cell therapy: bringing CAR-T to autoimmune disease https://t.co/pU3aggJeDu @AbataTx @sonomabio @KyvernaT
Open
‘Treg’ cell therapy: bringing CAR-T to autoimmune disease

‘Treg’ cell therapy: bringing CAR-T to autoimmune disease

At least seven companies, including five richly funded startups, are developing cell-based treatments for inflammatory conditions, making it one of biotech’s most competitive fields. 

@big4bio shared
On Aug 10, 2022
RT @Big4BioSF: Prellis Biologics Appoints New #CEO, Raises $35 Million in Series C #Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics #DrugDiscovery and #DrugDevelopment https://t.co/UySxwABAX6 @BusinessWire @Prellisbio #biotech #LifeSciences #BayArea https://t.co/7JQ8StphKi
Open
Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development

Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development

Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35

@BentheFidler shared
On Aug 16, 2022
Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest https://t.co/U4DeAJHMh6 $MRK @orna_tx @endlessRNA
Open
Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest

Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest

The pharmaceutical company has formed an alliance with Orna and invested $100 million in its Series B round, hoping the young biotech’s approach could lead to multiple new vaccines and ...